用天然多糖和相关的结构-活性关系治疗炎症性肠病的研究进展
Jiaqi Chen1,2, Yanan Gao1,2, Yanqiu Zhang1
1Affiliated Hospital, Changchun University of Chinese Medicine, Changchun, 130021, China. cc_wmx@163.com.
Food & function
|May 13, 2024
概括
天然多糖因其安全性和有效性而显示出治疗炎症性肠病 (IBD) 的前景. 本综述探讨了它们的抗IBD活动,机制以及作为功能性食物的潜力.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 营养学科学 营养学科学
背景情况:
- 炎症性肠病 (IBD) 是一种慢性疾病,其致病机制不明,治疗选择有限.
- 目前的IBD治疗有副作用,限制了长期使用.
- 自然的多糖为IBD管理提供了更安全,更有效的替代方案.
研究的目的:
- 审查天然多糖的抗炎性肠病 (抗IBD) 活动.
- 探索多糖结构和抗IBD生物活性之间的关系.
- 总结IBD中多糖的潜在机制和临床应用.
主要方法:
- 关于天然多糖和其抗IBD作用的研究文献综述.
- 对多糖源 (植物,动物,微生物,藻类) 的分析.
- 探索结构-活动关系和拟议的行动机制.
主要成果:
- 自然的多糖具有显著的抗IBD作用.
- 聚糖体构成影响生物活性.
- 机制包括微生物群调节,减少炎症和屏障保护.
结论:
- 天然多糖是功能性食品和营养保健品在IBD预防和治疗中的有希望的候选者.
- 对结构活动关系的进一步研究可以优化治疗潜力.
- 多糖提供了一个可行的饮食方法来管理IBD.
相关概念视频
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
331
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
331
Inflammatory Bowel Disease IV: Pharmacological Management
126
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
126
Inflammatory Bowel Disease V: Surgical Management
145
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
145
Drugs for Treatment of Ulcerative Colitis in IBD
136
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
136
Drugs for Treatment of Constipation-Predominant IBS
160
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
160
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
131
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
131


